BPH

Waterjet ablation confers advantages over TURPHeat-free high-velocity waterjet ablation (Aquablation) for BPH performed with an image-guided robot-assisted platform (AquaBeam System) met its primary safety and efficacy endpoints in a phase III study.
Water vapor ablation yields positive results at 2 yearsTreatment of lower urinary tract symptoms/BPH with convective water vapor ablation (Rezum System) appears to provide significant improvement on two key outcome measures versus medical therapy at up to 2 years, according to a study presented at the AUA annual meeting in Boston.
5-ARI use does not raise erectile dysfunction riskThe risk of erectile dysfunction is not increased with the use of a 5-alpha-reductase inhibitor compared with an alpha-blocker for the treatment of BPH.
Data cast light on ED/5-ARI connection
Urologists no longer primary initiator of tamsulosinUrologists are no longer the primary initiators of tamsulosin (Flomax) therapy in the United States, suggests an analysis of pharmaceutical claims from more than 50 private health plans.
5-ARI may have adverse metabolic effectsAuthors of a recent study say that long-term therapy with a 5-alpha-reductase inhibitor was associated with increased glucose, increased glycated hemoglobin, and altered lipid profiles.
BPH/LUTS: OTC alpha-blocker use feasibleStudies of bipolar plasma vaporization of the prostate and thulium vapoenucleation were among the other noteworthy research in BPH/LUTS presented at the AUA annual meeting in Boston.
Burnout, biopsy, BPH, and more: Post-AUA reviewUrologist Henry Rosevear, MD, reviews his personal highlights from AUA 2017, along with a few bumps in the road.
Robotic prostatectomy usage increasing for BPHThe use of robot-assisted simple prostatectomy is increasing for the management of BPH in the United States. Patients were nearly seven times more likely to undergo RASP in 2011-2015 compared to 2003-2006, after adjusting for confounders.
Urethral lift: 5-year data point to procedure’s durabilityAnalyses of data from 5 years of prospective follow-up in the pivotal trial supporting regulatory approval of the prostatic urethral lift ([PUL] UroLift System, NeoTract) show that the minimally invasive procedure remains safe and provides rapid and durable benefits for men with symptomatic BPH.